šŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX Ā· Real-Time Price Ā· USD
7.22
-0.10 (-1.37%)
At close: Nov 20, 2026, 4:00 PM EST
7.23
+0.01 (0.14%)
After-hours: Nov 20, 2026, 7:33 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

ORLADEYO is expanding in pediatrics, with management expecting continued revenue growth and a plateau in share as oral competition arrives. Navenibart pivotal data are expected in Q3 2027, while cost reductions and rare-disease pipeline expansion support longer-term operating leverage.

Maury Raycroft
Biotech Analyst, Jefferies

Hi, everyone. My name is Maury Raycroft, and I am one of the biotech analysts at Jefferies. I would like to welcome Charlie Gayer, the CEO of BioCryst. Charlie is going to start off with a presentation and go through the company and where they are at commercially and with some of the pipeline programs. Then we will go into Q&A at the end. Without further ado, I will turn it over to Charlie.

Charlie Gayer
CEO, BioCryst Pharmaceuticals

Great. Thanks, Maury, and thanks to the Jefferies team for inviting us this year. We always enjoy this conference in London. Before I get started, I will be making some forward-looking statements. Those statements have risks. You can read about them in our presentation on our website. We will also refer to some non-GAAP financial measures. I thought this year we would do an old-school stand-up presentation, just because there is a lot going on in the HAE marketplace right now, and we wanted to give you our full perspective on our HAE portfolio, why we have so much confidence in what we are doing today and the future. It starts with this idea of we do have a portfolio, and the portfolio is growing. So, it begins with ORLADEYO capsules that has been on the market since late 2020.

We have seen over this time that ORLADEYO is about much more than just convenience. Patients actually get, the patients who remain on, get injectable-like efficacy, and I will show you some more of that information in a minute. So we have really strong patient retention, strong physician and patient preference. Recently, we have launched ORLADEYO pellets, starting with kids aged two to 11. It is the first targeted oral prophy product for that age group. As you can imagine, for kids to have an oral is so critical, and we see the potential of really changing how children grow up with HAE now that they have an oral option. Then recently, we got ORLADEYO pellets also approved for the 12 and up population with 150 mg, and we are excited about introducing that to physicians currently and patients very shortly.

Coming next year, top-line data for navenibart, which we believe could be a transformative product for this marketplace with the first product to have every three and six-month injectable dosing. The type of efficacy we have seen in phase II is already very strong, so 90%-plus reduction versus baseline with very durable response at both three and six-month dosing. As a kallikrein inhibitor, it is a known, just like ORLADEYO, it is a known mechanism that physicians and patients are very familiar with. The HAE marketplace is still growing after all the new product introductions. We see the prophylaxis segment being around 8,000 patients today, roughly 5,000 patients on injectable products, another 3,000 on oral, or not quite 3,000 yet, but we see over time it growing to 5,000-plus injectable, 3,000-plus oral. By the middle of the 2030s, around 10,000 patients on prophylaxis.

All right, let's kind of address the elephant in the room here, which is there's another oral prophylaxis coming and great results for that product. There's kind of a myth out there that for ORLADEYO, patients are just taking it today because it's convenient, but it's not very effective. What I'd like to show you is why we feel so strongly based on our clinical data and real-world evidence that the reality is, the patients who stay on ORLADEYO get really good efficacy, and that's why they stay on. If they don't, they move on to one of the other options. This reality is based in the over 1,600 patients in the U.S. that we have on therapy, over 1,500 U.S. prescribers this year. That's been growing by over 60 prescribers per quarter.

Still strong growth as more and more doctors get familiar with the ORLADEYO story and our data. It starts with the clinical data. Going back to our APeX-2 study, the patients who started on 150 mg, just over 50% of them made it to two years of therapy, and that just over 50% had a 91% reduction in attacks. When we started seeing this information, sharing it with physicians, it really changed the idea of ORLADEYO as a very effective drug, not just a convenient drug. What we see in the real world is, in that first year, about 60% of patients make it to 12 months. The number one reason they drop off is they're not getting the efficacy that they were looking for, so that's expected. But once they reach 12 months, the retention is very strong.

We have launched ORLADEYO in a sole source specialty pharmacy, and one of the reasons that we did this is to collect real-world evidence with patients over time. This has allowed us to build a database of literally hundreds, now over 1,000 patients of evidence, and we've been presenting and publishing this. What you see here is evidence from classic type 1 and 2 HAE, as well as patients with C1 normal, where patients are reporting, for type 1 and 2, getting down to about a third of an attack per month, which is a very competitive attack rate if you look at clinical data from other products.

The C1 normal patients, which classically had been a very underserved population, they have tremendous real-world success and are getting down from three to four attacks a month, down below one attack per month, those that find ORLADEYO to be effective for treating their attacks. Having the specialty pharmacy allows us, this is another thing that gives us great confidence, is we look at this all the time. This is a look of roughly the last 90 days, or sorry, 180 days of HAE patients with type 1 and type 2 HAE who are on ORLADEYO, and they report, 44% of them report being attack-free over that last six months, which again, we believe is a very competitive attack-free rate. About 70% of them report having two or fewer attacks.

A thing about attacks in the real world is, once a patient's on prophylaxis, those attacks tend to be less severe. In the end, a patient's decision about control is based on how many attacks they have, but also how manageable are the attacks. Those patients who stay on ORLADEYO report a low level of attacks and that the attacks are very manageable. That leads to, as you would expect, a high level of satisfaction when we survey our patients. What they say is, what would cause them to switch? Well, if they get some combination of much better efficacy, a better tolerability profile, side effects, and also, importantly, whether they think a lot about the service model, their access to reimbursement, all of which they get with ORLADEYO and with our patient services.

Another thing that we do over time that gives us great confidence is every year we do a large survey, not with just a few doctors or just a few patients, but we do a big conjoint analysis with 100 patients, 175 HAE treaters, and 50 payers to survey not just the current market and their views on current products, but everything that's coming in the future. We always put in front of the treaters and the patients the best possible profile for future products, whether it be navenibart, deucrictibant, gene editing, all of that. We show the best possible profile and then run it through a market simulation that we've been doing now since prior to launch that's been very predictive of the trajectory of ORLADEYO. This constantly shows what I'm describing, that the patients who are doing well expect to stay on therapy.

The physicians expect them to stay on therapy. So in the future, we expect ORLADEYO to continue to grow. With additional competition, that growth may slow down, but it's going to plateau. It's not going to decrease. As I said, the work that we've done has been highly predictive. Back in 2020, we predicted that in 2025, we would sell just over $500 million, and that's what ended up happening. Our repeated use of this method gives us great confidence in the future. Sorry, one other point just to mention here is that our guidance for this year, $625 million-$645 million. At this point, six weeks or so from the end of the year, we expect to end in the upper end of that guidance. Just a point on payer mix too. This has been very consistent since the launch of ORLADEYO.

About 60% of the patients are commercial, about a quarter Medicare, the rest mostly Medicaid, and a few other government payers. We've been making steady improvements in payment rate, getting close to 85% overall. Just to put it in context, at this point, a percentage point improvement equals about $10 million of annualized revenue. I mentioned the sole source pharmacy just in terms of how we go to market. That's been a critical piece for gathering that long-term evidence, but it also gives us very fast near-term evidence. So it's stuff that our sales force uses to act quickly with customers, and then the service level that they provide has been critical, and we get really high marks from patients and HCPs in terms of level of satisfaction with the pharmacy and with our overall patient services and Empower Patient Services.

Then we have a 40-person sales force in eight regions out there. When we launch navenibart in a couple of years, that will stay the same. This is a thing with our commercialization of our HAE portfolio. We don't need to increase costs in the future as the portfolio grows. We've already got a very skilled team covering the market, and they are excited about the pediatrics indication today and extremely excited about navenibart coming in the not-so-distant future. In terms of pediatrics, the uptake of this in the first few months has been stronger than we expected. Maybe this goes back to our APeX-P data where we saw patients getting down to a median monthly attack rate of zero attacks, no AEs causing discontinuations in that study. The pediatric marketplace is underserved, underdeveloped.

We've identified about 500 patients in claims, but if the epidemiology is the same as adults, it should be more like 1,200. In the early days, we are seeing about a third of patients coming to ORLADEYO pellets, switching from other prophy. About a third are coming to prophy from acute-only therapy, and then the other third are new to HAE therapy. We think an oral option here gives kids with HAE a chance to grow up very differently than their parents or their grandparents did. They can grow up with very few attacks, and that can have a benefit, and we've actually published on this. There's benefit in terms of being able to go to school, healthcare resource use.

You can imagine kind of the psychological benefit too for families and for kids of feeling that freedom, feeling less fear, and that can have a long-term benefit for kids' lives. We see this as an opportunity for transforming how HAE is treated. Navenibart, again, very excited about what we're seeing here in the phase II data with excellent reduction at both the three and the six-month dosing levels. We expect a label with both doses and the flexibility to choose one or the other. It's the same amount of navenibart that a patient will take in a year, but they'll either take one two milliliter auto-injector every three months or two every six months.

That reduction in dosing burden with a mechanism of kallikrein inhibition that they know, with a very low level of injection site pain because of the formulation, physicians and patients are very excited about this coming. That three-month dosing really captures their attention. The addition of the six-month really encourages the potential future switch, and so we're excited to launch this in a couple of years. What do we see going forward for our HAE portfolio? $625 million-$645 million this year will come in at the upper end of that guidance, on top of a cost base for BioCryst that's actually been coming down. We've already lowered our OPEX guidance for the year once. We lowered the bottom end at our Q3 earnings to $415 million-$425 million.

As the impact of the closure of our discovery facilities is fully realized in 2027, we actually expect that OPEX to come down further. As we think about our current portfolio going forward, OPEX will grow very little, and the revenue will continue to grow. The $1.4 billion- $2 billion of portfolio that we put in there in the mid-30s, that comes from analyst consensus. That is the range of analyst views on our portfolio. We put that out there. We have not put a specific guidance for our portfolio, but the range seems reasonable. We think we can probably do better than $1.4 billion. All of this on a very stable, low-cost basis gives us an amazing amount of operating leverage, which we plan to use to build our portfolio of other rare disease assets.

Both products have IP protection out to the early 2040s, so there is a long period of cash generation in this portfolio. Will not go through all of this, but mainly just to point out, we ended Q3 with very strong cash position, $376 million. You can see the GAAP and non-GAAP operating profit continues to get stronger. It is getting stronger every quarter. As we go into 2027, we expect that trend to continue. Then finally, our overall portfolio. I have talked about HAE, talked about navenibart coming with pivotal data reading out in Q3 of next year for both the 12-month and six-month results. We are excited to report out on our Netherton syndrome product by the end of this year, just in the next few weeks.

That will tell us whether we think we have a product that can go forward in this very serious rare skin condition where there are currently no approved therapies. We look forward to near-term updates on that program. Maury, with that, I will take your questions in the last few minutes.

Maury Raycroft
Biotech Analyst, Jefferies

Okay. Sounds good. Thanks, Charlie. Maybe just going back to one of the earlier slides where you had the 30% in there from the survey work that you did, which would be 30% of the prophy opportunity. Did you test the respondents with a profile where deucrictibant was not on the market? What did that look like?

Charlie Gayer
CEO, BioCryst Pharmaceuticals

Yeah. Maury's question's around the annual work that we do, how we test future competitors. For deucrictibant, we just did this survey again this summer, right before the deucrictibant data came out. The profile that we had was actually, of course, one pill once a day, no side effects, and slightly better efficacy than they actually achieved. They had a great result, but we always like to handicap ourselves as much as possible. We think the data that we have from the summer is very representative of what the market thinks and how the market will act when deucrictibant comes out.

Maury Raycroft
Biotech Analyst, Jefferies

I guess the question is, did you test it? What was the baseline? If you're going to 30%, where are you at right now in that survey?

Charlie Gayer
CEO, BioCryst Pharmaceuticals

Oh, in terms of market share?

Maury Raycroft
Biotech Analyst, Jefferies

Yeah.

Charlie Gayer
CEO, BioCryst Pharmaceuticals

ORLADEYO across not just in prophy, but across all treated patients, has about 22%-23% market share at this point. We see that continuing to grow into about the mid-20% and then holding more or less flat.

Maury Raycroft
Biotech Analyst, Jefferies

Can you contextualize the 30% then? From where you are at currently, what kind of a reduction does that look like if deucrictibant lands on the market?

Charlie Gayer
CEO, BioCryst Pharmaceuticals

Not so much a reduction, Maury. It is more of a plateauing, right? What we expect is that when deucrictibant comes out, we will still get new patient prescriptions because of all the experience the marketplace has with ORLADEYO. But they will too. It is a great product, right? We will not get quite as many new prescriptions as before, but the patients who are doing really well on ORLADEYO are going to stick. We basically see ourselves plateauing. We will still be growing in the pediatric part of the market, but overall, probably a plateauing.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Same thing with navenibart. Where does the opportunity go once navenibart is on the market, and what does that share look like?

Charlie Gayer
CEO, BioCryst Pharmaceuticals

The biggest opportunity is the 5,000+ patients who are on injectable. Like I mentioned, the profile, there have been some recent advances in injectable therapy, generally moving from every two weeks to every four weeks for patients, and some patients like that. But what we are seeing is, unless patients are having trouble with efficacy, it is not very motivating to move. But when they see every three-month dosing and every six-month dosing, the physicians and the patients see a lot of switching happening. We think that is our biggest segment. Then, of course, with a portfolio, if you are not doing well on ORLADEYO, you want to switch, we have the opportunity to catch a lot of those patients with navenibart in the future. We see those as our two biggest opportunities.

Maury Raycroft
Biotech Analyst, Jefferies

Is there anything else in the phase III readout from Q3 next year that would cause people to switch to navenibart that you're going to be focused on, besides the convenience factor?

Charlie Gayer
CEO, BioCryst Pharmaceuticals

Yeah, I think, well, it's the convenience, it's competitive efficacy, which we fully expect based on our phase II result, and it is reports of AEs. We expect low AEs, particularly injection site pain. The market leader today, and we expect in the future, to be TAKHZYRO when navenibart launches. Same mechanism, but painful injections because of the inclusion of citric acid. So navenibart has a different formulation. It'll be launched in auto-injectors, and that extra benefit is something that's meaningful to patients as they think about switching.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. With deucrictibant launching, could there be any issues on the pricing or payer front if a patient's on deucrictibant, they're having fewer breakthrough attacks, so maybe it's less expensive for that patient overall? I guess, how could that play out from a pricing payer perspective?

Charlie Gayer
CEO, BioCryst Pharmaceuticals

I think the way you described that is what we believe is a fallacy. The patients on ORLADEYO aren't going to be having more attacks. The ones that stay on are going to be having a competitive low rate of attacks, and we have the evidence to show that to payers. It's been tremendously powerful so far in getting patients paid at this point. The other thing is that ORLADEYO is well-established with payers, and then we're going to have a portfolio. So we feel good about our overall portfolio relative to payers. Look, I think what you'll see is that we and others are going to price our products based on the value that it's providing to patients, and all of these therapies have provided tremendous value to HAE patients.

Maury Raycroft
Biotech Analyst, Jefferies

And so a majority of the patients that you anticipate staying on ORLADEYO, it is going to fall in that 44% group that are attack-free?

Charlie Gayer
CEO, BioCryst Pharmaceuticals

Well, it is the patients, 44% of them are attack-free, very low level of attacks for the others, very low life impact of those attacks. That is who is staying on today. That is who will stay on in the future.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. For the Netherton update, anything additional on higher setting expectations there, and maybe talk about next steps based on the results that you see?

Charlie Gayer
CEO, BioCryst Pharmaceuticals

So we will be reporting on up to 12 patients in part four of our study. What we will be looking for, the primary endpoint basically is the IASI score. So it is similar to the EASI score in atopic dermatitis. What we are hearing from physicians, from KOLs, is that because there are no therapies out there, a meaningful mean reduction across the populations would be about 25%. So we will be looking at that, and then we will be looking at responder rate. So if there is a smaller percentage, maybe a third, maybe half of patients in that group who are doing really well, those are the kind of things that are going to tell us what to do at the next stage. So we will be looking forward to, do we go to a pivotal study? Do we do more dose exploration, if we think that we have a drug?

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Okay. In your recent earnings update, you guys talked about, or announced the new scientific advisory board in place. What specifically is their mandate around external innovation? As the business becomes more profitable, has your BD appetite changed in terms of the stage, size, or type of assets that you want to in-license?

Charlie Gayer
CEO, BioCryst Pharmaceuticals

Yeah. Our SAB, we are thrilled that they joined us, and they joined us. This is not a figurehead kind of advisory board. This is a working advisory board. They are advisors who are working with us on a weekly basis as we think about our BD efforts, working with Sandeep and our BD team on this. We are looking at a lot of assets, a lot of rare disease areas. Our appetite for what we can do, of course, can grow as our profitability grows, as our cash position grows. But right now, we feel that we are well-positioned to bring in new products. We want to bring in things clinical stage, and we want to create a balanced pipeline. We have a great rare disease asset late stage.

We have a potential one early stage, and so we want to start filling in the middle so that we have a consistent pipeline.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Okay. Thanks so much, Charlie.

Charlie Gayer
CEO, BioCryst Pharmaceuticals

Great. Thanks, Maury.